Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
Catharina Ziekenhuis Eindhoven
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
Emory University
University of Miami
Mayo Clinic
Nantes University Hospital
Odense University Hospital
City of Hope Medical Center
National Institutes of Health Clinical Center (CC)
Memorial Sloan Kettering Cancer Center
Servicio de Salud Metropolitano Sur Oriente
City of Hope Medical Center
Eye & ENT Hospital of Fudan University
Vanderbilt-Ingram Cancer Center
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Vanderbilt-Ingram Cancer Center
University of Exeter
Eye & ENT Hospital of Fudan University
Eye & ENT Hospital of Fudan University
Sahlgrenska University Hospital
National Health Service, United Kingdom
E-DA Hospital
On Target Laboratories, LLC
E-DA Hospital
Mayo Clinic
Zhejiang Provincial People's Hospital
Eye & ENT Hospital of Fudan University
Eye & ENT Hospital of Fudan University
Memorial University of Newfoundland
University of Nottingham
Tata Memorial Centre
Sun Yat-sen University
University of Cambridge
Medtronic - MITG
Radboud University Medical Center
Wake Forest University Health Sciences
Gloucestershire Hospitals NHS Foundation Trust
Washington University School of Medicine
Washington University School of Medicine
Royal Marsden NHS Foundation Trust
Catholic University of the Sacred Heart
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Changhai Hospital
University Medical Center Groningen
Clinical Research Support Center Kyush